Management of Thrombotic Complications in COVID-19: An Update
| Autor: | Adrija Hajra, Sandipan Chakraborty, Carl J. Lavie, Maedeh Veyseh, Wilbert S. Aronow, Dhrubajyoti Bandyopadhyay, Somedeb Ball, Sheetal Vasundara Mathai |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
2019-20 coronavirus outbreak Coronavirus disease 2019 (COVID-19) Critical Illness Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Pneumonia Viral Pharmacology toxicology Review Article Betacoronavirus medicine Humans Pharmacology (medical) Intensive care medicine Pandemics SARS-CoV-2 business.industry Anticoagulants COVID-19 Thrombosis Venous Thromboembolism medicine.disease Critical illness Coronavirus Infections business Venous thromboembolism Thrombotic complication |
| Zdroj: | Drugs |
| ISSN: | 1179-1950 0012-6667 |
| DOI: | 10.1007/s40265-020-01377-x |
| Popis: | Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV‑2), is now a global pandemic. This virus primarily affects the respiratory tract and causes lung injury characterized by acute respiratory distress syndrome. Although the pathophysiology of COVID-19 is not yet clear, the most widely accepted mechanism is systemic inflammation. A clinically significant effect of the inflammation is coagulopathy. As a result of this effect, patients are found to have a high risk of venous thromboembolism. Studies have reported a high incidence of thrombotic complications in critically ill patients with COVID-19. In this review, we discuss the most updated evidence on the pathophysiology, diagnosis, and treatment of the coagulopathy of COVID-19. Prophylactic anticoagulation is recommended for all in-patients with COVID-19. Those with a higher risk of developing thromboembolic events or who have already developed venous thromboembolism should be treated with therapeutic anticoagulation. We also discuss post-discharge prophylaxis for high-risk patients and some newly proposed treatments for the hypercoagulability that could improve the outcomes of the affected patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink